A securities class action lawsuit has been filed against Regeneron Pharmaceuticals Inc. (REGN), alleging the company violated federal securities laws. Investors who purchased REGN shares have until Sept. 14, 2026, to seek appointment as lead plaintiff. The lawsuit was filed by Bronstein, Gewirtz & Grossman LLC on behalf of affected shareholders.
A securities class action lawsuit filed against Regeneron Pharmaceuticals Inc. alleges the company violated federal securities laws, with a Sept. 14 lead plaintiff deadline for investors.
"Investors who suffered losses are encouraged to seek recovery before the deadline," Bronstein, Gewirtz & Grossman LLC, the law firm that filed the complaint, said in a statement.
The lawsuit claims Regeneron made false or misleading statements and failed to disclose material information to shareholders, constituting securities fraud under federal law. The class action covers investors who purchased Regeneron securities during the period specified in the complaint.
The lead plaintiff deadline of Sept. 14, 2026, gives investors roughly six weeks to file motions. A lead plaintiff serves as the representative party acting on behalf of other class members in directing the litigation. Investors may also remain absent class members and share in any potential recovery without serving as lead plaintiff.
Regeneron, a biotechnology company based in Tarrytown, New York, develops treatments for eye diseases including macular degeneration, cancer, and inflammatory conditions. The company's stock trades on the Nasdaq under the ticker REGN.
The lawsuit adds legal uncertainty for Regeneron shareholders, potentially exposing the company to financial penalties and reputational damage. Investors will watch for any settlement announcements or court rulings that could determine the scope of potential damages. The next key date is the lead plaintiff deadline on Sept. 14, followed by the court's decision on lead counsel appointment.
This article is for informational purposes only and does not constitute investment advice.
